Radiation proctitis (RP) is a condition analogous to oral mucositis in the oral cavity, concerning the inflammation and damage to lower parts of the colon following pelvic radiation to the region. Rectal mucositis, a broader condition, can also be caused by factors other than radiation, including bacterial, viral or fungal infections, parasites, contact allergies or food allergies, and surgery. It is estimated that there are in excess of 250,000 new cases of prostate, cervical, rectal, testicular, bladder and endometrial cancer diagnosed each year. Approximately 50% of these patients require radiation therapy, and roughly 75% of patients undergoing pelvic irradiation experience radiation proctitis. Access is actively evaluating commercialization options for ProctiGard™, including the seeking of global marketing partners.
About Rectal Mucositis / Radiation Proctitis Rectal mucositis, and specifically radiation proctitis, is the inflammation and damage to the lower portion of the colon, primarily the sigmoid colon and rectum, after exposure to x-rays or ionizing radiation as part of radiation therapy. RP is most common after treatments for cancer, such as cervical, colon, and prostate cancer. RP can be acute, occurring within weeks of initiation of therapy, or can occur months or years after treatment, and symptoms include diarrhea, nausea, cramps, urgency, mucus discharge and painful defecation. Experts believe that RP occurs due to damage to the blood vessels that occurs as part of the radiation therapy.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for MuGard and Cobalamin, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the
Keywords for this news article include:
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Bently Creates Alabama Small Business Commission
- When to Say No to Investors, Yes to Mentors
- Bolivar Appointed to NSHMBA National Board
- Rosneft Growth Slowed by Western Sanctions
- SBA Kicks off Hispanic Heritage Month
- Duke Energy, Strata Partner on Big Solar Project
- Lindsay Lohan Claims She Handled Whitney Houston's Body Bag
- Ukraine Offers Temporary Autonomy to Rebel-held Areas
- Cat Stevens Touring U.S., First Since 1970s
- Thousands Risk Losing Health Care Aid